Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

"Quick update from Lori, Andrew is doing so well with continued clean scans and strength after ANKTIVA + NK cell therapy. Plus the latest on our FDA advocacy, the new documentary, and how we’re pushing to make these treatments available to more cancer patients nationwide. Cancer is losing this... show more

Lori Mills

53,807 subscribers

19,414 views • 2 months ago •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

Andrew and I are in Washington, D.C. today, where I had the honor of testifying before the FDA on behalf of cancer patients everywhere. We’re fighting to bring #ANKTIVA and natural killer (NK) cell therapies into the spotlight, giving hope and new options to those who need them most. Please watch the testimony. I hope it resonates with you. Together, we’re pushing for real progress. Bullish Dr. Pat Soon-Shiong

Andrew and I are in Washington, D.C. today, where I had the honor of testifying before the FDA on behalf of cancer patients everywhere. We’re fighting to bring #ANKTIVA and natural killer (NK) cell therapies into the spotlight, giving hope and new options to those who need them most. Please watch the testimony. I hope it resonates with you. Together, we’re pushing for real progress. Bullish Dr. Pat Soon-Shiong

Lori Mills

117,985 views • 3 months ago

Andrew and I were in Washington, D.C. last week, where I had the honor of testifying before the FDA on behalf of cancer patients everywhere. We’re fighting to bring #ANKTIVA and natural killer (NK) cell therapies into the spotlight — giving real hope and new options to those who need them most. Here is a clip of my testimony. Please watch and share. Let’s get eyes on ANKTIVA and natural killer cells and push for real progress together! Bullish Dr. Pat Soon-Shiong

Andrew and I were in Washington, D.C. last week, where I had the honor of testifying before the FDA on behalf of cancer patients everywhere. We’re fighting to bring #ANKTIVA and natural killer (NK) cell therapies into the spotlight — giving real hope and new options to those who need them most. Here is a clip of my testimony. Please watch and share. Let’s get eyes on ANKTIVA and natural killer cells and push for real progress together! Bullish Dr. Pat Soon-Shiong

Lori Mills

48,974 views • 3 months ago

In case you missed it 👀 From patient to minister - hear about Ashley Dalton MP's cancer journey and how she's leading the National Cancer Plan. Working with patients and charities, we're focused on quicker diagnosis, latest treatments and helping people live well with cancer.

In case you missed it 👀 From patient to minister - hear about Ashley Dalton MP's cancer journey and how she's leading the National Cancer Plan. Working with patients and charities, we're focused on quicker diagnosis, latest treatments and helping people live well with cancer.

Department of Health and Social Care

20,655 views • 7 months ago

Andrew’s fight is bigger than just our family. His case is now being featured in a documentary for the Soon-Shiong Clinic as we continue pushing forward — not only for him, but for every cancer patient who deserves access to innovative treatment options like NK cell therapy and #ANKTIVA. We are fighting for expanded access. We are fighting for hope. We are fighting for the patients who are told “there’s nothing left.” No family should have to battle bureaucracy while battling cancer. Please keep Andrew in your prayers and help us raise awareness so other patients can explore every possible option. The fight continues.

Andrew’s fight is bigger than just our family. His case is now being featured in a documentary for the Soon-Shiong Clinic as we continue pushing forward — not only for him, but for every cancer patient who deserves access to innovative treatment options like NK cell therapy and #ANKTIVA. We are fighting for expanded access. We are fighting for hope. We are fighting for the patients who are told “there’s nothing left.” No family should have to battle bureaucracy while battling cancer. Please keep Andrew in your prayers and help us raise awareness so other patients can explore every possible option. The fight continues.

Lori Mills

11,718 views • 6 months ago

Update- I hope everyone had a wonderful Thanksgiving. Tomorrow, Andrew begins the Patrick Soon-Shiong trial with ANKTIVA. His lymphocyte count has been dropping from radiation and chemo, and our prayer is to see those numbers rise—along with a strong surge in natural killer cells. We’re not just fighting for Andrew. We’re fighting for every cancer patient who deserves access to hope and real options. Our mission is to help push the FDA to approve this therapy nationwide, so no family is left without a chance. Andrew has another blood panel on Wednesday, and we’ll update you as soon as we see what his counts are doing. Thank you for standing with us through every step of this journey.

Update- I hope everyone had a wonderful Thanksgiving. Tomorrow, Andrew begins the Patrick Soon-Shiong trial with ANKTIVA. His lymphocyte count has been dropping from radiation and chemo, and our prayer is to see those numbers rise—along with a strong surge in natural killer cells. We’re not just fighting for Andrew. We’re fighting for every cancer patient who deserves access to hope and real options. Our mission is to help push the FDA to approve this therapy nationwide, so no family is left without a chance. Andrew has another blood panel on Wednesday, and we’ll update you as soon as we see what his counts are doing. Thank you for standing with us through every step of this journey.

Lori Mills

59,351 views • 9 months ago

This #WorldCancerResearchDay, we’re proud to highlight our global partnerships in the fight against cancer. Through our collaboration in Kenya, UoM Biology, Medicine and Health is advancing research on oesophageal cancer and pushing the boundaries to create lasting impact.

This #WorldCancerResearchDay, we’re proud to highlight our global partnerships in the fight against cancer. Through our collaboration in Kenya, UoM Biology, Medicine and Health is advancing research on oesophageal cancer and pushing the boundaries to create lasting impact.

The University of Manchester

395,009 views • 2 years ago

🚨ImmunityBio’s Anktiva: A New FDA-Approved Immunotherapy for certain bladder cancer. They are also developing treatments that may reduce the need for strong chemo, for blood cancer, lung cancer, brain cancer, and more. Broader approvals may take time. Someone call the President and fast-track this. Dr. Pat Soon-Shiong leads development beyond typical biotech efforts. Most cancer medicines, like chemotherapy, work by poisoning fast-growing cells to kill the cancer. This also hurts healthy cells, causing side effects like hair loss and weakness. Anktiva is different. It is an immunotherapy that wakes up your body’s own immune cells; natural killer cells and T cells to hunt and destroy cancer cells themselves. It acts like a booster shot for your immune system, using a protein called IL-15 to make these cells multiply and remember how to fight cancer long-term. ImmunityBio is different from most companies because of 3 big unique things: 1. They wake up 3 kinds of fighter cells at the same time: • NK cells (natural killers) • CD8 T cells (main attackers) • CD4 T cells (helpers) These three work together like a basketball team. This makes the body remember the cancer for a long time (maybe years). 2. They have a special cell line called NK-92. → It’s like buying frozen pizza instead of making dough from scratch every time. Doctors can just thaw it and give it to any patient. No need to take cells from the sick kid, customize them, and make them super weak with hospital chemo (that’s what normal CAR-T does). 3. Their medicine Anktiva gives a long, steady boost to the immune cells. Older drugs (like IL-2) gave a short, crazy boost that made people very sick. Anktiva is seems safer, so far. Exciting to follow the development. Interview: Chris Cuomo (NewsNation) — “Killing Cancer”

🚨ImmunityBio’s Anktiva: A New FDA-Approved Immunotherapy for certain bladder cancer. They are also developing treatments that may reduce the need for strong chemo, for blood cancer, lung cancer, brain cancer, and more. Broader approvals may take time. Someone call the President and fast-track this. Dr. Pat Soon-Shiong leads development beyond typical biotech efforts. Most cancer medicines, like chemotherapy, work by poisoning fast-growing cells to kill the cancer. This also hurts healthy cells, causing side effects like hair loss and weakness. Anktiva is different. It is an immunotherapy that wakes up your body’s own immune cells; natural killer cells and T cells to hunt and destroy cancer cells themselves. It acts like a booster shot for your immune system, using a protein called IL-15 to make these cells multiply and remember how to fight cancer long-term. ImmunityBio is different from most companies because of 3 big unique things: 1. They wake up 3 kinds of fighter cells at the same time: • NK cells (natural killers) • CD8 T cells (main attackers) • CD4 T cells (helpers) These three work together like a basketball team. This makes the body remember the cancer for a long time (maybe years). 2. They have a special cell line called NK-92. → It’s like buying frozen pizza instead of making dough from scratch every time. Doctors can just thaw it and give it to any patient. No need to take cells from the sick kid, customize them, and make them super weak with hospital chemo (that’s what normal CAR-T does). 3. Their medicine Anktiva gives a long, steady boost to the immune cells. Older drugs (like IL-2) gave a short, crazy boost that made people very sick. Anktiva is seems safer, so far. Exciting to follow the development. Interview: Chris Cuomo (NewsNation) — “Killing Cancer”

Black Panther Capital

40,249 views • 7 months ago

Ivermectin + Mebendazole: The Cancer Study That Changes the Conversation. Two anti-infective drugs. Both already FDA-approved. Both already widely available. Together they reduce cancer cell proliferation, cut off the tumor's blood supply, and trigger cancer cell self-termination. 84% net clinical benefit across prostate, breast, and lung cancer patients. The National Cancer Institute needs to move on this now. Join the Fight: Courtesy of Real America's Voice Real America's Voice (RAV), American Sunrise #MedicalFreedom

Ivermectin + Mebendazole: The Cancer Study That Changes the Conversation. Two anti-infective drugs. Both already FDA-approved. Both already widely available. Together they reduce cancer cell proliferation, cut off the tumor's blood supply, and trigger cancer cell self-termination. 84% net clinical benefit across prostate, breast, and lung cancer patients. The National Cancer Institute needs to move on this now. Join the Fight: Courtesy of Real America's Voice Real America's Voice (RAV), American Sunrise #MedicalFreedom

McCullough Foundation

15,826 views • 5 months ago

"This isn't just a cancer therapy. This is a way of liberating people from the burden of having a disease that could come back and kill you." On #WorldCancerDay, our 2018 medicine laureates reflect on the hope their remarkable cancer therapy gives to patients around the globe.

"This isn't just a cancer therapy. This is a way of liberating people from the burden of having a disease that could come back and kill you." On #WorldCancerDay, our 2018 medicine laureates reflect on the hope their remarkable cancer therapy gives to patients around the globe.

The Nobel Prize

101,885 views • 3 years ago

Thank you so much for your incredible support and continued generosity. It’s finally happening! Andrew and I are flying to Washington, D.C. tomorrow, and I will be testifying before the FDA to help get natural killer cells and ANKTIVA released and available to all cancer patients. I can't promise it will happen, but I can promise I'm fighting for you. Please keep us in your prayers. Your kindness has truly meant the world to us. We would not be able to make this trip without your support, and we are so deeply grateful. Here’s a quick update...

Thank you so much for your incredible support and continued generosity. It’s finally happening! Andrew and I are flying to Washington, D.C. tomorrow, and I will be testifying before the FDA to help get natural killer cells and ANKTIVA released and available to all cancer patients. I can't promise it will happen, but I can promise I'm fighting for you. Please keep us in your prayers. Your kindness has truly meant the world to us. We would not be able to make this trip without your support, and we are so deeply grateful. Here’s a quick update...

Lori Mills

53,389 views • 3 months ago

Quick update: Andrew has an MRI tomorrow night (Friday). I’m asking every prayer warrior reading this to cover him. We’re believing for another completely normal brain scan, that would be number five. Please pray. These results matter far beyond our family. They strengthen the fight to get #ANKTIVA and natural killer cell therapy released nationwide for every patient who needs it. Thank you. We feel every prayer

Quick update: Andrew has an MRI tomorrow night (Friday). I’m asking every prayer warrior reading this to cover him. We’re believing for another completely normal brain scan, that would be number five. Please pray. These results matter far beyond our family. They strengthen the fight to get #ANKTIVA and natural killer cell therapy released nationwide for every patient who needs it. Thank you. We feel every prayer

Lori Mills

22,067 views • 1 month ago

Megyn Kelly sat down with Dr. Patrick Soon-Shiong to discuss his revolutionary cancer protocol—a treatment that has already extended lives by years for patients with terminal diagnoses, including the late Senator Harry Reid. The Science Behind the Breakthrough Dr. Soon-Shiong’s approach challenges conventional cancer treatments like chemotherapy and radiation, which destroy the immune system’s natural killer (NK) cells and T-cells—critical for fighting cancer. His BioStripe treatment works by rebuilding the immune system, even in patients who have exhausted all other options. Real Patients, Miraculous Results Merkel cell carcinoma (5th-line treatment): Complete remission—patient lived 6+ years and didn’t die from cancer. Bladder cancer: Patients still alive 10-11 years later. Triple-negative breast cancer: Multiple complete remissions. Metastatic pancreatic cancer: One patient disease-free after 5 years, now 6+ years and counting. FDA Roadblocks & Lost Time Despite undeniable success, Dr. Soon-Shiong faced years of resistance from regulators. In 2015, he proposed testing his method before chemo/radiation—but the FDA insisted on starting with end-stage patients. After 700,000 pages of submissions, approval finally came in late 2024. The Future: Beyond Cancer This treatment isn’t just for cancer—it’s showing promise against sepsis and severe infections. One recent case: A Valley Fever patient on a ventilator, given last rites—fully recovered after treatment. The Urgent Question Why is bureaucracy slowing down a therapy that could save millions? With pancreatic cancer, glioblastoma, and lung cancer patients still dying every day, how many more lives could have been saved if this had been fast-tracked?

Megyn Kelly sat down with Dr. Patrick Soon-Shiong to discuss his revolutionary cancer protocol—a treatment that has already extended lives by years for patients with terminal diagnoses, including the late Senator Harry Reid. The Science Behind the Breakthrough Dr. Soon-Shiong’s approach challenges conventional cancer treatments like chemotherapy and radiation, which destroy the immune system’s natural killer (NK) cells and T-cells—critical for fighting cancer. His BioStripe treatment works by rebuilding the immune system, even in patients who have exhausted all other options. Real Patients, Miraculous Results Merkel cell carcinoma (5th-line treatment): Complete remission—patient lived 6+ years and didn’t die from cancer. Bladder cancer: Patients still alive 10-11 years later. Triple-negative breast cancer: Multiple complete remissions. Metastatic pancreatic cancer: One patient disease-free after 5 years, now 6+ years and counting. FDA Roadblocks & Lost Time Despite undeniable success, Dr. Soon-Shiong faced years of resistance from regulators. In 2015, he proposed testing his method before chemo/radiation—but the FDA insisted on starting with end-stage patients. After 700,000 pages of submissions, approval finally came in late 2024. The Future: Beyond Cancer This treatment isn’t just for cancer—it’s showing promise against sepsis and severe infections. One recent case: A Valley Fever patient on a ventilator, given last rites—fully recovered after treatment. The Urgent Question Why is bureaucracy slowing down a therapy that could save millions? With pancreatic cancer, glioblastoma, and lung cancer patients still dying every day, how many more lives could have been saved if this had been fast-tracked?

Camus

615,893 views • 1 year ago

"This isn't just a cancer therapy. This is a way of liberating people from the burden of having a disease that could come back and kill you." On World Cancer Day, medicine laureates James Allison and Tasuku Honjo share their personal experiences with cancer and the hope their remarkable cancer treatment - immunotherapy - gives to patients around the globe. #WorldCancerDay

"This isn't just a cancer therapy. This is a way of liberating people from the burden of having a disease that could come back and kill you." On World Cancer Day, medicine laureates James Allison and Tasuku Honjo share their personal experiences with cancer and the hope their remarkable cancer treatment - immunotherapy - gives to patients around the globe. #WorldCancerDay

The Nobel Prize

16,921 views • 1 year ago

Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): It’s fully approved in the US for one rare form of bladder cancer… but not for the common form most patients have. So even though the same drug is already FDA-approved and sitting in their files, he can’t use it off-label for other patients without insane one-patient-at-a-time paperwork, IRB delays, and individual FDA sign-off. Meanwhile, Saudi Arabia (with their own sophisticated FDA) reviewed the exact same 1.7 million pages of data and approved it for more cancers. His blunt takeaway: Cancer is a war against time. Patients are forced to fly to Saudi Arabia for access… or wait in bureaucratic limbo while the clock runs out. “I’m completely befuddled as to why this molecule… that stimulates your NK cells is not allowed to give to people who have low NK cells.” If a drug is already FDA-approved and sitting in their own files, why the insane barriers to using it for other patients who are dying? Is this protecting people… or protecting something else?

Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): It’s fully approved in the US for one rare form of bladder cancer… but not for the common form most patients have. So even though the same drug is already FDA-approved and sitting in their files, he can’t use it off-label for other patients without insane one-patient-at-a-time paperwork, IRB delays, and individual FDA sign-off. Meanwhile, Saudi Arabia (with their own sophisticated FDA) reviewed the exact same 1.7 million pages of data and approved it for more cancers. His blunt takeaway: Cancer is a war against time. Patients are forced to fly to Saudi Arabia for access… or wait in bureaucratic limbo while the clock runs out. “I’m completely befuddled as to why this molecule… that stimulates your NK cells is not allowed to give to people who have low NK cells.” If a drug is already FDA-approved and sitting in their own files, why the insane barriers to using it for other patients who are dying? Is this protecting people… or protecting something else?

Camus

51,195 views • 7 months ago

On World Cancer Day, we stand with everyone affected by cancer and honour the strength of survivors and families in Ontario and around the world. Our government is supporting cancer care and research with record investments, including by speeding up access to lifesaving cancer medications. Find out more:

On World Cancer Day, we stand with everyone affected by cancer and honour the strength of survivors and families in Ontario and around the world. Our government is supporting cancer care and research with record investments, including by speeding up access to lifesaving cancer medications. Find out more:

Doug Ford

32,522 views • 7 months ago

The Pillars of Cancer Treatment Are a Lie. Chemo and Radiation Aren't Just Brutal—They're Actively Destroying Your Natural Killer Cells, the Very Thing Standing Between You and Cancer. A stunning revelation from Dr. Patrick Soon-Shiong that reframes our entire battle against cancer. He shares a truth 460 million years in the making. Within every one of us is an ancient gift, a cell bestowed by the very process of creation: the Natural Killer (NK) cell. Dr. Soon-Shiong explains that this cell is our fundamental biological shield, the key reason humanity has survived infection, trauma, and cancer across millennia. Yet, for decades, modern medicine has waged a devastating war on this very protector. How? With the very pillars of our oncological arsenal: high-dose chemotherapy, radiation, steroid therapy, and even newer modalities. These treatments, while aimed at cancer, systematically destroy the NK cells designed to defend us. A single dose of radiation can obliterate this natural defense for a year, leaving patients vulnerable. Dr. Soon-Shiong presents a paradigm-shattering question: What if, instead of attacking the body’s innate protection, we learned to unlock and unleash it? The answer is here. After a lifetime of research, a method has been discovered and approved to activate the body as its own factory. A single intervention—a “bio-shield”—that proliferates these natural killer cells, empowering them to do what they were designed to do: protect you from cancer. The results? Real patients with bladder cancer, free of disease for a decade. This is not a future promise. This is a present reality, approved in 2024. Dr. Soon-Shiong credits the current administration for its role in moving this breakthrough forward for the entire nation. The era of destroying the body to save it is ending. The era of activating our 460-million-year-old innate defense has begun.

The Pillars of Cancer Treatment Are a Lie. Chemo and Radiation Aren't Just Brutal—They're Actively Destroying Your Natural Killer Cells, the Very Thing Standing Between You and Cancer. A stunning revelation from Dr. Patrick Soon-Shiong that reframes our entire battle against cancer. He shares a truth 460 million years in the making. Within every one of us is an ancient gift, a cell bestowed by the very process of creation: the Natural Killer (NK) cell. Dr. Soon-Shiong explains that this cell is our fundamental biological shield, the key reason humanity has survived infection, trauma, and cancer across millennia. Yet, for decades, modern medicine has waged a devastating war on this very protector. How? With the very pillars of our oncological arsenal: high-dose chemotherapy, radiation, steroid therapy, and even newer modalities. These treatments, while aimed at cancer, systematically destroy the NK cells designed to defend us. A single dose of radiation can obliterate this natural defense for a year, leaving patients vulnerable. Dr. Soon-Shiong presents a paradigm-shattering question: What if, instead of attacking the body’s innate protection, we learned to unlock and unleash it? The answer is here. After a lifetime of research, a method has been discovered and approved to activate the body as its own factory. A single intervention—a “bio-shield”—that proliferates these natural killer cells, empowering them to do what they were designed to do: protect you from cancer. The results? Real patients with bladder cancer, free of disease for a decade. This is not a future promise. This is a present reality, approved in 2024. Dr. Soon-Shiong credits the current administration for its role in moving this breakthrough forward for the entire nation. The era of destroying the body to save it is ending. The era of activating our 460-million-year-old innate defense has begun.

Camus

150,992 views • 11 months ago

Of all the casualties in the war on cancer, the most critical have been the most ignored: your NK and T cells. As Dr. Patrick Soon-Shiong explains, while oncology has long treated the anemia and neutropenia caused by chemotherapy, it has overlooked the destruction of the very immune cells that fight cancer. For 35 years, there was no treatment for this catastrophic side effect. That era is over. Dr. Soon-Shiong announces ANKTIVA, the first FDA-approved therapy proven to activate NK cells, T cells, and memory T cells. The result? Documented complete responses in bladder cancer patients, free of disease for over nine years. This breakthrough shatters a long-standing medical blind spot. Whether from chemo, radiation, or a severe viral infection, the body's primary defense is often wiped out. ANKTIVA represents a paradigm shift—from solely attacking disease to actively re-arming the patient's own immune system. The future of medicine is not just fighting the enemy, but empowering the army within.

Of all the casualties in the war on cancer, the most critical have been the most ignored: your NK and T cells. As Dr. Patrick Soon-Shiong explains, while oncology has long treated the anemia and neutropenia caused by chemotherapy, it has overlooked the destruction of the very immune cells that fight cancer. For 35 years, there was no treatment for this catastrophic side effect. That era is over. Dr. Soon-Shiong announces ANKTIVA, the first FDA-approved therapy proven to activate NK cells, T cells, and memory T cells. The result? Documented complete responses in bladder cancer patients, free of disease for over nine years. This breakthrough shatters a long-standing medical blind spot. Whether from chemo, radiation, or a severe viral infection, the body's primary defense is often wiped out. ANKTIVA represents a paradigm shift—from solely attacking disease to actively re-arming the patient's own immune system. The future of medicine is not just fighting the enemy, but empowering the army within.

Camus

55,260 views • 11 months ago

I am told this therapy will be available across the country in major cancer hospitals, providing new hope to patients and their families. Moreover, this affordable treatment can be made available to all patients across the world. That will be in tune with our vision of “Vasudhaiva Kutumbakam”.

I am told this therapy will be available across the country in major cancer hospitals, providing new hope to patients and their families. Moreover, this affordable treatment can be made available to all patients across the world. That will be in tune with our vision of “Vasudhaiva Kutumbakam”.

President of India

158,543 views • 2 years ago

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.

Camus

422,251 views • 11 months ago